SEC Stock Data Quick Answer Aardvark Therapeutics, Inc. reported Cash and Equivalents of $47.05 million for fiscal year 2025. Aardvark Therapeutics, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $47.05M -23.7% 2024 $61.64M — Quarterly Cash and Equivalents Quarter Ending Cash and Equivalents YoY QoQ September 30, 2025 $39.28M — +51.1% … Read more
Quick Answer Aardvark Therapeutics, Inc. reported Total Assets of $117.18 million for fiscal year 2025. Aardvark Therapeutics, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $117.18M +51.2% 2024 $77.51M — Quarterly Total Assets Quarter Ending Total Assets YoY QoQ September 30, 2025 $133.23M — -9.7% June 30, 2025 $147.47M — … Read more
Quick Answer Aardvark Therapeutics, Inc. reported Diluted EPS of $2.93 per share (loss) for fiscal year 2025. Aardvark Therapeutics, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$2.93 +43.1% 2024 -$5.15 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ September 30, 2025 -$0.75 +28.6% -13.6% June 30, 2025 … Read more
Quick Answer Aardvark Therapeutics, Inc. reported Net Income of -$57.59 million for fiscal year 2025. Aardvark Therapeutics, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$57.59M -179.7% 2024 -$20.59M — Quarterly Net Income Quarter Ending Net Income YoY QoQ September 30, 2025 -$16.32M -290.1% -13.6% June 30, 2025 -$14.37M -163.7% … Read more
Quick Answer Aardvark Therapeutics, Inc. reported Net Income of -$57.59 million for fiscal year 2025. Aardvark Therapeutics, Inc. — Key Financials by Year Metric 2025 2024 2023 Net Income -$57.59M-179.7% -$20.59M — Diluted EPS -$2.93+43.1% -$5.15 — Total Assets $117.18M+51.2% $77.51M — Cash and Equivalents $47.05M-23.7% $61.64M — Stockholders Equity $106.63M+295.1% -$54.64M-57.0% -$34.80M R&D Expense … Read more
Quick Answer Antiaging Quantum Living Inc. reported Shares Outstanding of 30.00 million shares for fiscal year 2024. Antiaging Quantum Living Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2024 30.00M +0.0% 2023 30.00M +0.0% 2022 30.00M +0.0% 2021 30.00M +0.0% 2020 30.00M +200.4% 2019 9.98M -0.1% 2018 9.99M +0.0% 2017 9.99M … Read more
Quick Answer Antiaging Quantum Living Inc. reported Gross Profit of $428.5 thousand for fiscal year 2025. Antiaging Quantum Living Inc. Gross Profit — Annual History Fiscal Year Gross Profit YoY Change 2025 $428.5K +6269.2% 2024 $6.7K -50.5% 2023 $13.6K +115.9% 2022 $6.3K +110.0% 2021 $3.0K — Quarterly Gross Profit Quarter Ending Gross Profit YoY QoQ … Read more
Quick Answer Antiaging Quantum Living Inc. reported Operating Income of -$790.0 thousand for fiscal year 2025. Antiaging Quantum Living Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$790.0K -91.3% 2024 -$413.0K -1027.5% 2023 -$36.6K +18.6% 2022 -$45.0K +38.3% 2021 -$72.9K -31.5% 2020 -$55.4K +2.9% 2019 -$57.1K -3771.3% 2018 $1.6K +225.0% … Read more
Quick Answer Antiaging Quantum Living Inc. reported Stockholders Equity of -$1.13 million for fiscal year 2025. Antiaging Quantum Living Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 -$1.13M -173.5% 2024 -$413.2K -379.8% 2023 -$86.1K -74.0% 2022 -$49.5K -719.0% 2021 -$6.0K -110.0% 2020 $60.5K +210.4% 2019 $19.5K -18.1% 2018 $23.8K +1120.7% … Read more
Quick Answer Antiaging Quantum Living Inc. reported Cash and Equivalents of $370.5 thousand for fiscal year 2025. Antiaging Quantum Living Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $370.5K +122.5% 2024 $166.6K +46948.6% 2023 $354.00 -97.5% 2022 $14.3K -18.4% 2021 $17.5K -71.5% 2020 $61.5K +1384.4% 2019 $4.1K +174.1% … Read more